AGEN vs SMMT
AGEN: A clinical-stage immuno-oncology company advancing checkpoint immunotherapy and combination therapies, primarily botensilimab, while generating near-term revenue through royalty sales and partnerships. SMMT: A biopharmaceutical company dedicated to the clinical advancement of its lead bispecific antibody, ivonescimab, for oncology applications.
Side-by-side fundamentals
| Metric | AGEN | SMMT | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $6.19 | $14.98 | |
| Market cap as of 2026-07-25 | $276M | $10.6B | |
| P/E as of 2026-07-25 | 4.27 | n/a | |
| PEG as of 2026-07-25 | n/a | -1.21 | |
| Net margin as of 2026-07-25 | +52.2% | -9027.1% | AGEN higher |
| Gross margin as of 2026-07-25 | +99.3% | n/a | |
| Operating margin as of 2026-07-25 | +87.9% | -8108.3% | AGEN higher |
| ROE as of 2026-07-25 | +76.6% | -291.2% | AGEN higher |
| ROA as of 2026-07-25 | +31.1% | -243.1% | AGEN higher |
| Debt / equity as of 2026-07-25 | 4.01 | 0.00 | SMMT lower |
| Revenue growth (YoY) as of 2026-07-25 | +24.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +5.2% | n/a | |
| Beta as of 2026-07-25 | 1.37 | -1.34 | |
| 1-year return as of 2026-07-23 close | -1.0% | -46.5% | AGEN higher |
Fundamentals: Finnhub, as of 2026-07-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.